COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00640952
Recruitment Status : Withdrawn (PI left site)
First Posted : March 21, 2008
Last Update Posted : November 13, 2015
National Parkinson Foundation
Information provided by (Responsible Party):
Joohi Jimenez-Shahed, Baylor College of Medicine

Brief Summary:
The purpose of this study is to determine how many patients with Parkinson's disease have compulsive behaviors, and what types of behaviors they have. This study will also determine if acamprosate can be used to treat compulsive behaviors in Parkinson's disease patients.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: acamprosate Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease
Study Start Date : August 2006
Actual Primary Completion Date : September 2008
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: acamprosate
    333 mg 2 tabs tid

Primary Outcome Measures :
  1. safety and efficacy compared to baseline scores [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. change from baseline assessment tools used in the study [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Idiopathic Parkinson's disease
  2. Active dopaminergic therapy at stable dose for one month (levodopa or dopamine agonist)
  3. Able and willing to complete Rating Scales
  4. Presence of one or more compulsive behavior based on responses to Rating Scales (defined as >5 on the SOGS; >17 on the YBOCS-SV and YBOCS-CUV; >1.7 on the SCS for women and >2.1 on the SCS for men; >15 on the YBOCS-BE, >5.5 on the CQ).
  5. Written informed consent

Inclusion criteria (controls):

  1. No significant psychiatric disease
  2. Able and willing to complete Rating Scales
  3. Written informed consent

Exclusion Criteria:

  1. No anticipated need for adjustment of medications for Parkinson's disease
  2. Current participation in another clinical study
  3. History of unstable psychiatric disease (as determined by the Principal Investigator)
  4. Women of childbearing age not using appropriate contraceptive methods (oral contraceptives, condoms, surgery)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00640952

Layout table for location information
United States, Texas
PDCMDC 6550 Fannin, Suite 1801
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
National Parkinson Foundation
Layout table for investigator information
Principal Investigator: Joohi Jimenez-Shahed, MD Baylor College of Medicine
Additional Information:
Layout table for additonal information
Responsible Party: Joohi Jimenez-Shahed, Principal Investigator, Baylor College of Medicine Identifier: NCT00640952    
Other Study ID Numbers: H-19781
First Posted: March 21, 2008    Key Record Dates
Last Update Posted: November 13, 2015
Last Verified: November 2015
Keywords provided by Joohi Jimenez-Shahed, Baylor College of Medicine:
Parkinson's disease
impulse control behaviors
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Compulsive Behavior
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Impulsive Behavior
Alcohol Deterrents